INKT cell regulator liposome composition and method of use
Liposome compositions with IMM60 and specific lipids stabilize iNKT cell activation, addressing overstimulation issues and improving immune response efficacy for enhanced cancer treatment.
JP2026517843APending Publication Date: 2026-06-02アイオーエックス セラピューティクス リミテッド
Patent Information
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- アイオーエックス セラピューティクス リミテッド
- Filing Date
- 2024-05-03
- Publication Date
- 2026-06-02
Smart Images
Figure 2026517843000001_ABST
Abstract
Provided herein are compositions comprising liposomes containing compound A(A) (wherein n is 1(IMM60), 2(IMM70), or 3(IMM80)), or a salt, ester, solvate, or hydrate thereof, and two or more lipids or salts thereof, and uses thereof, including methods for stimulating an immune response. Furthermore, the present invention provides a liposome comprising at least one therapeutic agent and a phospholipid bilayer comprising at least two phospholipids selected from 1,2-distearoyl-sn-glycero-3-phospho-rac-glycerol (DSPG), 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC), and 1,2-dipalmitoyl-sn-glycero-[phosphol-rac-(1-glycerol)] (DPPG), wherein the phospholipids substantially lack cholesterol, plant sterols, and polyethylene glycolate lipids (PEG lipids).
Need to check novelty before this filing date? Find Prior Art